Transcriptomics

Dataset Information

0

Dual Relief of T-Lymphocyte Proliferation and Effector Function Underlies Response to PD-1 Blockade in Epithelial Malignancies


ABSTRACT: Although understanding of T-cell exhaustion is widely based on mouse models, its analysis in cancer patients could provide clues indicating tumor sensitivity to immune checkpoint blockade (ICB). Data suggests a role for costimulatory pathways, particularly CD28, in exhausted T-cell responsiveness to PD-1/PD-L1 blockade. Here, we used single-cell transcriptomic, phenotypic, and functional approaches to dissect the relation between CD8+ T-cell exhaustion, CD28 costimulation, and tumor specificity in head and neck, cervical, and ovarian cancers. We found that memory tumor-specific CD8+ T cells, but not bystander cells, sequentially express immune checkpoints once they infiltrate tumors leading, in situ, to a functionally exhausted population. Exhausted T cells were nonetheless endowed with effector and tumor residency potential but exhibited loss of the costimulatory receptor CD28 in comparison to their circulating memory counterparts. Accordingly, PD-1 inhibition improved proliferation of circulating tumor-specific CD8 T cells and reversed functional exhaustion of specific T cells at tumor sites. In agreement with their tumor specificity, high infiltration of tumors by exhausted cells was predictive of response to therapy and survival in ICB-treated head and neck cancer patients. Our results showed that PD-1 blockade–mediated proliferation/reinvigoration of circulating memory T cells and local reversion of exhaustion occur concurrently to control tumors.

ORGANISM(S): Homo sapiens

PROVIDER: GSE148162 | GEO | 2020/05/01

REPOSITORIES: GEO

Dataset's files

Source:
Action DRS
Other
Items per page:
1 - 1 of 1

Similar Datasets

2021-10-12 | GSE178245 | GEO
2020-05-01 | GSE145896 | GEO
2010-10-03 | E-GEOD-24026 | biostudies-arrayexpress
2016-08-02 | E-GEOD-84105 | biostudies-arrayexpress
2022-02-17 | PXD026447 | Pride
2023-07-01 | GSE200506 | GEO
2023-06-16 | GSE206325 | GEO
2016-10-31 | GSE86797 | GEO
2022-08-19 | GSE211352 | GEO
2016-10-31 | GSE86796 | GEO